Cargando…

Pathways to Endocrine Therapy Resistance in Breast Cancer

Breast cancers with positive expression of Estrogen Receptor (ER+) are treated with anti-hormone/endocrine therapy which targets the activity of the receptor, the half-life of the receptor or the availability of estrogen. This has significantly decreased mortality in women with ER+ breast cancer, ho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Haque, Md. Moquitul, Desai, Kartiki V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6712962/ https://www.ncbi.nlm.nih.gov/pubmed/31496995 http://dx.doi.org/10.3389/fendo.2019.00573

Ejemplares similares

JMJD6 orchestrates a transcriptional program in favor of endocrine resistance in ER+ breast cancer cells
por: Das, Partha, et al.
Publicado: (2022)

Editorial: Resistance to Endocrine Therapies in Cancer
por: Ranganathan, Prathibha, et al.
Publicado: (2020)

Endocrine Resistance in Hormone Receptor Positive Breast Cancer–From Mechanism to Therapy
por: Rani, Aradhana, et al.
Publicado: (2019)

The role of the tumor microenvironment in endocrine therapy resistance in hormone receptor-positive breast cancer
por: Yuan, Jie, et al.
Publicado: (2023)

The Tumor Microenvironment as a Regulator of Endocrine Resistance in Breast Cancer
por: Diaz Bessone, María Inés, et al.
Publicado: (2019)

Molecular Mechanisms of Endocrine Resistance in Estrogen-Receptor-Positive Breast Cancer
por: Belachew, Esmael Besufikad, et al.
Publicado: (2021)

Corrigendum: Molecular Mechanisms of Endocrine Resistance in Estrogen-Receptor-Positive Breast Cancer
por: Belachew, Esmael Besufikad, et al.
Publicado: (2021)

The Role of Ki67 in Evaluating Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer
por: Zhang, Ailin, et al.
Publicado: (2021)

Non-canonical Estrogen Signaling in Endocrine Resistance
por: Ranganathan, Prathibha, et al.
Publicado: (2019)

Autoimmune Disease in Women: Endocrine Transition and Risk Across the Lifespan
por: Desai, Maunil K., et al.
Publicado: (2019)

Targeted radionuclide therapy in endocrine-related cancers: advances in the last decade
por: Al-Toubah, Taymeyah, et al.
Publicado: (2023)

Editorial: Endocrine-related cardiovascular diseases: Recent advances in diagnosis and treatment
por: Bhat, Audesh, et al.
Publicado: (2023)

The PI3K/Akt Pathway in Tumors of Endocrine Tissues
por: Robbins, Helen Louise, et al.
Publicado: (2016)

Editorial: DNA damage response pathways meet endocrine systems
por: Werner, Haim, et al.
Publicado: (2023)

Hypoxia signaling pathway: A central mediator in endocrine tumors
por: Watts, Deepika, et al.
Publicado: (2023)

Editorial: Endocrine and metabolic diseases – genetic impact and therapies
por: Jéru, Isabelle, et al.
Publicado: (2022)

Endocrine Disrupting Chemicals: Effects on Endocrine Glands
por: Lauretta, Rosa, et al.
Publicado: (2019)

Comparison of dyslipidemia incidence in Chinese early-stage breast cancer patients following different endocrine therapies: A population-based cohort study
por: Wang, Junren, et al.
Publicado: (2022)

Characterizing Endocrine Status, Tumor Hypoxia and Immunogenicity for Therapy Success in Epithelial Ovarian Cancer
por: Pereira, Madison, et al.
Publicado: (2021)

Identification and characterization of TP53 gene Allele Dropout in Li-Fraumeni syndrome and Oral cancer cohorts
por: Haque, Mohammed Moquitul, et al.
Publicado: (2018)

Editorial: Effects of pharmacologic therapy for diabetes mellitus on the endocrine system
por: Giagulli, VA, et al.
Publicado: (2022)

Editorial: Cell Signaling in Tumors of Endocrine and Endocrine-Responsive Tissues
por: Perks, Claire, et al.
Publicado: (2019)

Both EZH2 and JMJD6 regulate cell cycle genes in breast cancer
por: Biswas, Antara, et al.
Publicado: (2020)

Endocrine and paracrine characteristics of neuroendocrine prostate cancer
por: Arman, Tarana, et al.
Publicado: (2022)

Editorial: Biomolecular modifications in endocrine-related cancers
por: Zhan, Xianquan, et al.
Publicado: (2023)

Editorial: Hypoxia, oxidative stress, and endocrine cancers
por: Duvillié, Bertrand, et al.
Publicado: (2023)

Integrative Neuro-Endocrine Pathways in the Control of Reproduction in Lamprey: A Brief Review
por: Freamat, Mihael, et al.
Publicado: (2013)

Editorial: Endocrine and paracrine regulation of spermatogenesis
por: Goldberg, Erwin, et al.
Publicado: (2022)

An Overview of the Polymorphisms of Circadian Genes Associated With Endocrine Cancer
por: Morales-Santana, Sonia, et al.
Publicado: (2019)

Editorial: Further advances in understanding the endocrine cancer microenvironment
por: Coperchini, Francesca, et al.
Publicado: (2022)

Notch Signaling Pathway and Endocrine Resistance in Breast Cancer
por: Bai, Jing-Wen, et al.
Publicado: (2020)

Exploring new pathways in endocrine-resistant breast cancer
por: de Pinho, Inês Soares, et al.
Publicado: (2022)

Metabolism and Endocrine Disorders: What Wnt Wrong?
por: Franco, Carolina N., et al.
Publicado: (2022)

Grand Challenges in Cancer Endocrinology: Endocrine Related Cancers, an Expanding Concept
por: Belfiore, Antonino, et al.
Publicado: (2013)

Disruption in Thyroid Signaling Pathway: A Mechanism for the Effect of Endocrine-Disrupting Chemicals on Child Neurodevelopment
por: Ghassabian, Akhgar, et al.
Publicado: (2018)

Metabolic Regulation of Epithelial to Mesenchymal Transition: Implications for Endocrine Cancer
por: Bhattacharya, Debasmita, et al.
Publicado: (2019)

Obesity and endocrine-related cancer: The important role of IGF-1
por: Zhong, Wentao, et al.
Publicado: (2023)

Editorial: Endocrine Frailty in the Elderly
por: Aversa, Antonio, et al.
Publicado: (2019)

Editorial: Endocrine Disrupters and Metabolism
por: Gibert, Yann, et al.
Publicado: (2019)

Endocrine Regulation on Bone by Thyroid
por: Zhu, Siyuan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qjcjlbl5fer4356825sa1u59cr